

**References for CEQUA® (cyclosporine ophthalmic solution) 0.09% CEQUA White Space  
NPP DM Wave 2**

**References:**

1. Johnston, J. Effect of OTX-101 0.09% on corneal staining and SANDE scores in patients with dry eye disease uncontrolled on cyclosporine ophthalmic emulsion 0.05%. Abstract presented at American Academy of Optometry 2023; October 12, 2023; New Orleans, LA.
2. Data on file. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.
3. Effect of CEQUA in Subjects with Dry Eye Disease, ClinicalTrials.gov identifier NCT04357795. Updated Sept 09, 2022. Accessed August 29, 2023. <https://www.clinicaltrials.gov/study/NCT04357795>
4. US Patent 9,937,225 B2.
5. Cholkar K, Gilger BC, Mitra AK. Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery. *Transl Vis Sci Technol.* 2015;4(3):1-16.
6. Mandal A, Bisht R, Rupenthal ID, Mitra A. Polymeric micelles for ocular drug delivery: from structural frameworks to recent preclinical studies. *J Control Release.* 2017;248:96-116.

Current as of January 27, 2025

© 2025 Sun Pharmaceutical Industries, Inc. All rights reserved. CEQUA is a registered trademark of Sun Pharmaceutical Industries Limited. All other trademarks are the property of their respective owners.

PM-US-CQA-1791 1/2025